Tritoterelin for breast cancer – pro
While ovarian suppression with tamoxifen is appropriate, Trelstar is a drug that has been approved for prostate cancer. It had not been extensively studied for breast cancer, as were the alternatives, goserelin and Lupron. There seems no reason to favor this drug over the alternatives, without studies. One study, by Lambertini et al found it to be effective, but it had nto been compared with goserelin or LLUpron, which have been used for emany decades.
Triptorelin is a gonadotropin-releasing hormone agonist. By causing constant stimulation of the pituitary, it decreases pituitary secretion of gonadotropins luteinizing hormone (LH) and follicle stimulating hormone (FSH). Like other GnRH agonists, triptorelin may be used in the treatment of hormone-responsive cancers such as prostate cancer.
Watson Pharma. Trelstar LA 11.25 mg (triptorelin pamoate for injectable suspension) prescribing information. Corona, CA: 2006 Aug.
Heyns, Chris F Triptorelin in the Treatment of Prostate Cancer: Clinical Efficacy and Tolerability, American Journal of Cancer:
2005 – Volume 4 – Issue 3 – pp 169-183
Lambertini M, Boni L, Michelotti A, et al. Ovarian suppression with triptorelin during adjuvant breast cancer chemotherapy and long-term ovarian function, pregnancies, and disease-free survival. JAMA. 2015;314(24):2632-2640.
Meredith M. Regan et al, Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone ReceptorPositive, Human Epidermal Growth Factor Receptor 2Negative Early Breast Cancer: TEXT and SOFT Trials. of Clinical Oncology 34, no. 19 (July 2016) 2221-2231.
NCCN, Breast Cancer 2017